{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069892","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.021982+00:00","generated_at":"2026-06-07T13:31:40.307098+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CRISPR amends Vertex collaboration on exa-cel; $20M contingent payment, cost deferral adjustments","bullets":["CRISPR agrees to pay Vertex $20M contingent payment upon specified event under Amendment No. 1 for exa-cel.","Deferral of CRISPR's share of costs capped at $25M annually; amounts offset against future exa-cel profitability.","Amendment allocates costs from a new third-party license agreement entered by Vertex; some details redacted.","Changes timing and portion of CRISPR's permitted cost deferrals under certain specified circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069892","json":"https://secwatch.observer/filing/0000950170-23-069892.json","markdown":"https://secwatch.observer/filing/0000950170-23-069892.md","text":"https://secwatch.observer/filing/0000950170-23-069892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/0000950170-23-069892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/crsp-20231212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:31:40.307098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b826146711bdd2cd5d2d5cd5db6e5a586cd893b3","claim":"CRISPR Therapeutics AG amended Amendment No. 1 with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (effective 2023-12-12).","evidence_excerpt":"On December 12, 2023, CRISPR Therapeutics AG, CRISPR Therapeutics Limited, CRISPR Therapeutics, Inc., and TRACR Hematology Ltd (together, “CRISPR”) entered into an amendment to the Amended and Restated Joint Development and Commercialization Agreement (the “Amendment No. 1”) with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, “Vertex”), related to the global development, manufacturing, and commercialization of exagamglogene autotemcel, or exa-cel (formerly CTX001).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/0000950170-23-069892-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited"},{"label":"Effective","value":"2023-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}